Optimising the Therapeutic Window: A Systematic Review and Network Meta‐Analysis of Pregabalin Dosing Strategies for Painful Diabetic Neuropathy

Key Points

• To evaluate the effectiveness and safety of different pregabalin doses for treating painful diabetic neuropathy.
• Systematic review of existing literature on pregabalin dosing strategies
• Network meta-analysis to compare efficacy and safety
• Focus on doses of ≤150 mg, 300 mg, and 600 mg per day
• Pregabalin at doses ≤150 mg/day showed no significant benefit compared to placebo
• Doses of 300 mg and 600 mg/day resulted in significant pain reduction
• Pregabalin 300 mg/day exhibited a better safety profile compared to 600 mg/day, which had more adverse events

Abstract